JAM
TXMD icon

Jupiter Asset Management’s TherapeuticsMD TXMD Stock Holding History

Jupiter Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,778
Closed -$403K – 652
2021
Q2 		$403K Hold
6,778
– – ﹤0.01% 511
2021
Q1 		$454K Buy
+6,778
New +$531K ﹤0.01% 493

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jupiter Asset Management's TXMD Position: Q3 2021 in Review

Jupiter Asset Management sold out of TherapeuticsMD (TXMD) in Q3 2021, closing a stake of 6,778 shares — an estimated $403K sold.

Jupiter Asset Management first reported a position in TXMD in Q1 2021 and held it in 2 quarters. The position peaked at $454K in Q1 2021. 149 funds tracked by Wall St. Rank hold TXMD as of Q3 2021.

  • Jupiter Asset Management reported no remaining TherapeuticsMD position as of Q3 2021 after selling out during the quarter.
  • Jupiter Asset Management sold 6,778 TherapeuticsMD shares in Q3 2021, an estimated $403K.
  • Jupiter Asset Management first reported a position in TherapeuticsMD in Q1 2021 and held it in 2 quarters.
  • Jupiter Asset Management's TherapeuticsMD position peaked at $454K in Q1 2021.
  • 149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2021.

Based on Jupiter Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.